Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06751082

Real World Observational Study of Sotatercept for Pulmonary Hypertension

The purpose of this study seeks to describe the real world initial experience with sotatercept in the treatment of pulmonary hypertension.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location status: Recruiting

Location contact

Robert Frantz, M.D.

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults age 18 or greater who are being treated with sotatercept in the Mayo Pulmonary hypertension clinic.

Exclusion criteria

  • Adults lacking capacity to consent

Treatment and study plan

Primary outcomes

  1. EmPHasis10 Questionnaire

    Time frame: Baseline, Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10

    The EmPHasis10 Questionnaire consists of 10 questions to assess quality of life. The scores can range from 0-50, a higher score indicates a worse quality of life.

  2. Number of pulmonary hypertension vasodilator medications taken by a subject

    Time frame: Baseline, Year 10

    Pulmonary hypertension vasodilator medications are used to decrease pressure in the pulmonary arteries.

  3. Number of patients to have a change in dose of prostanoid medications

    Time frame: Baseline, Year 10

    A change in dose of prostanoid medications will be determined by a change from baseline dosage.

  4. Number of patient hospitalizations

    Time frame: Baseline, Year 10

    Number of patient hospitalizations will be determined by the number of patients admitted into the hospital.

  5. Number of patients to cease therapy sessions

    Time frame: Baseline, Year 10

    Cease of therapy session will be determined by a patient's termination of all therapy sessions

  6. Number of patients to discontinue prostanoid therapy

    Time frame: Baseline, Year 10

    Number of patients to discontinue prostanoid therapy will be determined by a patients termination of all prostanoid therapy

  7. Number of patients with bleeding complications

    Time frame: Baseline, Year 10

    Bleeding complications include nosebleeds not requiring ER visit or transfusion, epistaxis or GI hemorrhage requiring ED visit/hospitalization.

  8. Number of patients to develop Skin telangiectasias

    Time frame: Baseline, Year 10

    Development of skin telangiectasias includes new development, worsening, or distribution

  9. Change in 6 min walk distance

    Time frame: Baseline, Year 10

    6 minute walk distance will be measured in meters (m).

  10. Number of patients to have a change in hemodynamics

    Time frame: Baseline, Year 10

    Change in hemodynamics include the change in Blood Flow, Blood Pressure, Cardiac Output, Vascular Resistance, Perfusion

  11. Change in Right Ventricular Systolic Pressure (RVSP)

    Time frame: Baseline, Year 10

    Right Ventricular Systolic Pressure is the pressure in the right ventricle during contraction. RVSP will be measured in mmHg.

  12. Right Ventricular Strain

    Time frame: Baseline, Year 10

    Right Ventricular Strain refers to strain on the right ventricle during contraction. Right Ventricular Strain will be determined by echocardiogram and measured as a percentage.

  13. Change in Right Ventricle (RV) function

    Time frame: Baseline, Year 10

    Change in RV function will be determined by echocardiogram and measured as a percentage.

  14. Change in capacitance

    Time frame: Baseline, Year 10

    Capacitance is the ability for blood vessels to store and release blood. capacitance will be determined by echocardiogram.

  15. Change in tricuspid regurgitation

    Time frame: Baseline, Year 10

    Tricuspid regurgitation is the regurgitation of blood into the right atrium during contraction of the heart.

  16. Change in Stroke Volume (SV)

    Time frame: Baseline, Year 10

    Stroke Volume is calculated by End-Diastolic Volume (EDV)-End-Systolic Volume (ESV) and measured in mL

  17. Change in Pulse Pressure (PP)

    Time frame: Baseline, Year 10

    Pulse Pressure is calculated by PP=systolic blood pressure (SBP) - diastolic blood pressure (DBP) and measured in mmHg

  18. Change in functional class

    Time frame: Baseline, Year 10

    Functional class refers to the severity of patients heart condition. A change in class would refer to the increase or decrease in severity of the condition.

  19. Number of patients to survive without receiving a transplant

    Time frame: Baseline, Year 10

    A transplant is defined as receiving an organ or tissue from a donor.

Study contacts

Contact information is provided by the study sponsor or research team.

Hayden Halbach, M.B.A.

CONTACT

[email protected]

507-255-2648

Louise Durst, R.N.

CONTACT

507-284-1838

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Sotatercept Pulmonary Hypertension Observational Registry

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 27, 2024
Registry last updated
Apr 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.